Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

IO

- PMLiVE

Merck chalks up another win for Keytruda in lung cancer

Becomes the first PD-1 inhibitor to improve OS in NSCLC patients when combined with chemo

AstraZeneca AZ

Clock starts ticking on AZ’s first-line lung cancer filing in US

FDA priority review of oncology treatment Tagrisso begins

- PMLiVE

Data backs up Roche’s Tecentriq/Avastin combo in lung cancer

Results will be used to pursue a first-line indication in NSCLC

- PMLiVE

Lung cancer data gives Roche’s Tecentriq a boost

Will help its PD-L1 inhibitor compete with Merck & Co’s Keytruda

- PMLiVE

Merck pulls Keytruda filing in Europe, despite US approval

Phase II KeyNote-0241 trial results failed to win over the EMA

- PMLiVE

MSD touts Keytruda first-line promise in NSCLC

Says patients on the drug more than doubled median OS compared to chemo

Eli Lilly HQ

Prospects for Lilly’s Verzenio hit by botched lung cancer trial

The CDK 4/6 inhibitor failed to improve overall survival in a late-stage study

AstraZeneca AZ

AZ starts pursuit of lung cancer indication for Imfinzi

And its EGFR inhibitor Tagrisso picks up US breakthrough status

Bristol-Myers Squibb (BMS) building

NICE says OK to Opdivo for lung cancer via CDF

Comes after BMS drops the price of its PD-1 inhibitor

- PMLiVE

AZ buoyed by latest lung cancer data at ESMO

Data from separate Tagrisso and Imfinzi trials show superior PFS among patients

Roche Basel Switzerland

UK is first to receive Roche’s rare lung cancer drug

Alecensa made available under MHRA's early access scheme

AstraZeneca AZ

After MYSTIC setback, FDA gives some comfort to AZ

Awards its PD-L1 inhibitor Imfinzi breakthrough status in locally-advanced NSCLC

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links